Pregnancy-associated plasma protein A - a level in first trimester and its impact on pregnancy outcome
Keywords:PAPP-A in pregnancy, Preterm delivery, Fetal growth restriction, PIH
Background: To study the pregnancy outcome in relation to PAPP-A level in the first trimester of pregnancy.
Methods: Every patient visiting the antenatal OPD was counseled for testing of first trimester screening to assess fetal wellbeing. Patients who were registered for the delivery in the same hospital were taken into consideration for study. Blood samples were taken at 11-13 weeks of gestation and sent to lab for analysis. Results were expressed in multiple of median and the patients having MoM value less than 0.5 were carefully observed till the delivery, and a thorough neonatal examination was done by a pediatrician.
Results: 524 patients were included in the study, out of which 452 patients were found to have a normal PAPP-A level of >0.5 MoM. All these patients were followed further during the antenatal period where 18 patients developed preterm labour and few patients developed pregnancy induced hypertension (PIH). The obstetric outcome of patients with normal PAPP-A level was fairly uneventful as compared to others with a low PAPP-A level.
Conclusions: PAPP-A level in the first trimester of pregnancy (11-13 weeks) is an important predictor of further obstetrics outcome. Patients having a PAPP-A level < 0.5 MoM had a high risk for preterm delivery, fetal growth restriction and stillbirth along with increased incidence of hypertensive disorder of pregnancy. A low PAPP-A level is a useful indicator of risk of preterm delivery and future chance of development of PIH.
Proctor LK, Toal M, Keating S. Placental size and the prediction of severe early onset intrauterine growth restriction in women with low pregnancy associated plasma protein A. Ultrasounds Obstet Gynecol. 2009;34(3):274-82.
Gagon A, Wilson RD, Audibert F. Obstetric complications associated with abnormal maternal serum marker analytes, J Obset Gynecol. 2008;30(10):918-49.
Jacob A, Canik JA, Messerlian GM. Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening.2010.
Krantz D, Goetz DL, Simpson JL. Association of extreme first trimester free human chorionic gonadotrophin-beta, pregnancy associated plasma protein A and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol. 2004;191(4):1452.
Spencer K, Cowans NJ, Chefetz I. First trimester maternal serum PP-13, PAPP-A and second trimester uterine artery Doppler pulsativity index as markers of preechlampsia. Ultrasound Obstet Gynecol. 2007;29(2):128-34.
Fillipi E, Stanghton J, Peregrine E, Jones P, Huttly W, Peebles DM. Uterine artery doppler and adverse pregnancy outcome in women with extreme levels of fetoplacental proteins used for down syndrome screening. Ultrasound Obstet Gynecol. 2011;37(5):520-7.
Cnossen JS, Morris RK, Riet G, Mol BW, van der Post JA, Coomarasamy A, et al. Use of uterine artery Doppler ultrasonography to predict preechlampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ. 2008;178(6):701-11.
Handschul K. Low PAPP-A: what are the clinical implications? Placenta. 2006;27(suppl A):S127-34.
Bowman CJ, Strack Rd, Chapin RE. Matrnal placental insulin-like growth factor (IGF) signaling and its importance to normal embryo fetal development. Birth defects Res B. 2013;17:10-8.
Kirkagard I, Uldberg N, Oxvig C. Biology of pregnancy associated plasma protein-a in relation to prenatal diagnostics; an overview. Acta obstet Gynecol Scand. 2010;89(9):1118-25. Ultrasound Obstet Gynecol. 2006;28:637-45
Cowans NJ, Spencer K. First trimester ADAM 12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin like growth factor system. Prenat Diagn. 2007;27(3):264-71.
Dugoff L, Hobbins JC, Malone FD. First trimester maternal serum PAPP-A and free beta Aubunit human chorionic gonadotrophin concentrations and nuchal translucency are associated with obstetric complications: a population based screening study (the FASTER trial). Am J Obstet Gynecol. 2004;19(6):1446-51.